Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-1 receptor type 1 (IL-1R1), also known as CD121a, is a transmembrane cytokine receptor that plays a central role in mediating immune and inflammatory responses. It is the primary signaling receptor for interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β). The extracellular region of IL-1R1 consists of three immunoglobulin-like domains that bind IL-1α and IL-1β, initiating a signaling cascade through the TIR domain, leading to NFκB activation and inflammatory responses. IL-1R1 is constitutively expressed on various cell types, including T cells, endothelial cells, and fibroblasts, and its expression can be upregulated during inflammation or immune activation. The interleukin 1 receptor antagonist (IL-1Ra) also binds to IL-1R1, blocking activation and serving as a natural antagonist to limit excessive inflammation.
IL-1Ra competes with IL-1α and IL-1β for binding to IL-1R1, preventing receptor activation and downstream signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-1 Receptor Type 1 (IL-1R1).